Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2)

Journal of Medicinal Chemistry

Volumn 50, Issue 11, 2007, Pages 2647-2654

  Anderson, David R ^a   Meyers, Marvin J ^a   Vernier, William F ^a   Mahoney, Matthew W ^a   Kurumbail, Ravi G ^a   Caspers, Nicole ^a   Poda, Gennadiy I ^a   Schindler, John F ^a   Reitz, David B ^a   Mourey, Robert J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 PHENYLPYRIDIN 4 YL) 1,5,6,7 TETRAHYDRO 4H PYRROLO[3,2 C]PYRIDIN 4 ONE TRIFLUOROACETIC ACID; 2 (2 PYRIMIDIN 5 YLPYRIDIN 4 YL) 1,5,6,7 TETRAHYDRO 4H PYRROLO[3,2 C]PYRIDIN 4 ONE TRIFLUOROACETIC ACID; 2 (2 QUINOLIN 3 YLPYRIDIN 4 YL) 1,5,6,7 TETRAHYDRO 4H PYRROLO [3,2 C]PYRIDIN 4 ONE; 2 (2 THIEN 3 YLPYRIDIN 4 YL) 1,5,6,7 TETRAHYDRO 4H PYRROLO [3,2 C]PYRIDIN 4 ONE TRIFLUOROACETIC ACID; 2 (2,4' BIPYRIDIN 4 YL) 1,5,6,7 TETRAHYDRO 4H PYRROLO[3,2 C] PYRIDIN 4 ONE TRIFLUOROACETIC ACID; 2 [2 (2 CHLOROPHENYL)PYRIDIN 4 YL] 1,5,6,7 TETRAHYDRO 4H PYRROLO[3,2 C]PYRIDIN 4 ONE TRIFLUOROACETIC ACID; 2 [2 (2 FLUOROPHENYL)PYRIDIN 4 YL] 1,5,6,7 TETRAHYDRO 4H PYRROLO[3,2 C]PYRIDIN 4 ONE TRIFLUOROACETIC ACID; 2 [2 (3 CHLOROPHENYL)PYRIDIN 4 YL] 1,5,6,7 TETRAHYDRO 4H PYRROLO[3,2 C]PYRIDIN 4 ONE TRIFLUOROACETIC ACID; 2 [2 (3 FLUOROPHENYL)PYRIDIN 4 YL] 1,5,6,7 TETRAHYDRO 4H PYRROLO[3,2 C]PYRIDIN 4 ONE TRIFLUOROACETIC ACID; 2 [2 (4 AMINOPHENYL)PYRIDIN 4 YL] 1,5,6,7 TETRAHYDRO 4H PYRROLO[3,2 C]PYRIDIN 4 ONE TRIFLUOROACETIC ACID; 2 [2 (4 FLUOROPHENYL)PYRIDIN 4 YL] 1,5,6,7 TETRAHYDRO 4H PYRROLO[3,2 C]PYRIDIN 4 ONE TRIFLUOROACETIC ACID; 2 [2 (4 METHOXYPHENYL)PYRIDIN 4 YL] 1,5,6,7 TETRAHYDRO 4H PYRROLO[3,2 C]PYRIDIN 4 ONE TRIFLUOROACETIC ACID; 2,4 DIOXOPIPERIDINE; 4 [4 (4 OXO 4,5,6,7 TETRAHYDRO 1H PYRROLO[3,2 C]PYRIDIN 2 YL) PYRIDIN 2 YL]BENZONITRILE TRIFLUOROACETIC ACID; CYCLIN DEPENDENT KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRROLOPYRIDINE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTALLOGRAPHY; DRUG ACTIVITY; DRUG EFFECT; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

ACUTE DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CRYSTALLOGRAPHY, X-RAY; HUMANS; INFLAMMATION; MODELS, MOLECULAR; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; PYRROLES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

EID: 34250181285     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0611004     Document Type: Article

References (21)

1. Camussi, G.; Lupia, E. The future role of anti-tumor necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs 1998, 55 (5), 613-620.
2. Braun, J.; Sieper, J. Role of novel biological therapies in psoriatic arthritis: Effects on joints and skin. BioDrugs 2003, 17 (3), 187-199.
3. Jarvis, B.; Faulds, D. Etanercept: A review of its use in rheumatoid arthritis. Drugs 1999, 57 (6), 945-966.
4. Richard-Miceli, C.; Dougados, M. Tumour necrosis factor-a blockers in rheumatoid arthritis: Review of the clinical experience. BioDrugs 2001, 15 (4), 251-259.
5. Seymour, H. E.; Worsley, A.; Smith, J. M.; Thomas, S. H. L. Anti-TNF agents for rheumatoid arthritis. Br. J. Clin. Pharmacol. 2001, 51 (3), 201-208.
6. Adams, J. L.; Badger, A. M.; Kumar, S.; Lee, J. C. p38 MAP kinase: Molecular target for the inhibition of pro-inflammatory cytokines. Prog. Med. Chem. 2001, 38, 1-60.
7. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Heyes, J. R.; Landvatter, S. W.; Strickler, J. E; McLaughlin, M. M.; Siemens, I. R.; Fisher, S. M.; Livi, G. P.; White, J. R.; Adams, J. L.; Young, P. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (London) 1994, 372 (6508), 739-746.
8. Haddad, J. J. VX-745, Vertex Pharmaceuticals. Curr. Opin. Invest. Drugs 2001, 2 (8), 1070-1076.
9. Dambach, D. M. Potential adverse effects associated with inhibition of p38α/β MAP kinases. Curr. Top. Med. Chem. 2005, 5, 929-939.
10. Ding, C. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr. Opin. Invest. Drugs 2006, 7, 1020-1025.
11. Kotlyarov, A.; Neininger, A.; Schubert, C.; Eckert, R.; Birchmeier, C.; Volk, H.-D.; Gaestel, M. MAPKAP kinase 2 is essential for LPS-induced TNF-a biosynthesis. Nat. Cell Biol. 1999, 1 (2), 94-97.
12. Winzen, R.; Kracht, M.; Ritter, B.; Wilhelm, A.; Chen, C.-Y. A.; Shyu, A.-B.; Muller, M.; Gaestel, M.; Resch, K.; Holtmann, H. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J. 1999, 18 (18), 4969-4980.
13. Gaestel, M. MAPKAP kinases - MKs - two's company, three's a crowd. Nat. Rev. Mol. Cell Biol. 2006, 7 (2), 120-130.
14. Anderson, D. R.; Mahoney, M. W.; Phillion, D. P.; Rogers, T. E.; Meyers, M. J.; Poda, G.; Hegde, S. G.; Singh, M.; Reitz, D. B.; Wu, K. K.; Buchler, I. P.; Xie, J.; Vernier, W. F. Preparation of pyrrolopyridinones as mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds. WO 2004/058762 A1, 2004.
15. LaMattina, J. L. The synthesis of 2-amino-4-(4-imidazolyl)pyridines. J. Heterocycl. Chem. 1983, 20 (3), 533-538.
16. Kurumbail, R. G.; Pawlitz, J. P.; Stegeman, R. A.; Stallings, W. C.; Shieh, H. S.; Mourey, R. M.; Bolten, S. L.; Broadus, R. M. Crystalline structure of human MAPKAP kinase-2. Patent application WO2003076333 A2, 2003.
17. Anderson, D. R.; Hegde, S.; Reinhard, E.; Gomez, L.; Vernier, W. F.; Lee, L.; Liu, S.; Sambandam, A.; Snider, P. A.; Masih, L. Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg. Med. Chem. Lett. 2005, 15 (6), 1587-1590.
18. Knight, Z. A.; Shokat, K. M. Features of selective kinase inhibitors. Chem. Biol. 2005, 12, 621-637.
19. Swinney, D. C. Biochemical mechanisms of drug action: what does it take for success? Nat. Rev. Drug Discovery 2004, 3, 801-808.
20. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
21. Stokoe, D.; Engel, K.; Campbell, D. G.; Cohen, P.; Gaestel, M. Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins. FEBS Lett. 1992, 313, 307-313.